Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hyman Muss

Showing results (51-60 of 68) with videos related to

Pageof 7
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 2, 2025
Adjuvant Dose-Dense Chemotherapy in Hormone Receptor-Positive Breast CancerOtto Metzger Filho, Karla Ballman, Jordan Campbell, et al.
Cancer|January 25, 2020
Associations between nutritional factors and chemotherapy toxicity in older adults with solid tumorsEfrat Dotan, William P Tew, Supriya G Mohile, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 18, 2016
Validation of a Prediction Tool for Chemotherapy Toxicity in Older Adults With CancerArti Hurria, Supriya Mohile, Ajeet Gajra, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 25, 2012
Six cycles of doxorubicin and cyclophosphamide or Paclitaxel are not superior to four cycles as adjuvant chemotherapy for breast cancer in women with zero to three positive axillary nodes: Cancer and Leukemia Group B 40101Lawrence N Shulman, Constance T Cirrincione, Donald A Berry, et al.
Cancer|October 6, 2005
Developing a cancer-specific geriatric assessment: a feasibility studyArti Hurria, Supriya Gupta, Marjorie Zauderer, et al.
The Oncologist|April 13, 2019
Older-Patient-Specific Cancer Trials: A Pooled Analysis of 2,277 Patients (A151715)Dyda Dao, Tyler Zemla, Aminah Jatoi, et al.
European Journal of Cancer (Oxford, England : 1990)|March 19, 2022
Effects of capecitabine as part of neo-/adjuvant chemotherapy - A meta-analysis of individual breast cancer patient data from 13 randomised trials including 15,993 patientsMarion T van Mackelenbergh, Fenja Seither, Volker Möbus, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|April 30, 2018
Factors associated with falls in older adults with cancer: a validated model from the Cancer and Aging Research GroupTanya M Wildes, Ronald J Maggiore, William P Tew, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 18, 2014
Comparison of doxorubicin and cyclophosphamide versus single-agent paclitaxel as adjuvant therapy for breast cancer in women with 0 to 3 positive axillary nodes: CALGB 40101 (Alliance)Lawrence N Shulman, Donald A Berry, Constance T Cirrincione, et al.
Breast Cancer Research and Treatment|March 12, 2017
Using ePrognosis to estimate 2-year all-cause mortality in older women with breast cancer: Cancer and Leukemia Group B (CALGB) 49907 and 369901 (Alliance A151503)Gretchen G Kimmick, Brittny Major, Jonathan Clapp, et al.
Pageof 7

Showing results (51-60 of 68) with videos related to

Sort By:
Pageof 7
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 2, 2025
Adjuvant Dose-Dense Chemotherapy in Hormone Receptor-Positive Breast CancerOtto Metzger Filho, Karla Ballman, Jordan Campbell, et al.
Cancer|January 25, 2020
Associations between nutritional factors and chemotherapy toxicity in older adults with solid tumorsEfrat Dotan, William P Tew, Supriya G Mohile, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 18, 2016
Validation of a Prediction Tool for Chemotherapy Toxicity in Older Adults With CancerArti Hurria, Supriya Mohile, Ajeet Gajra, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 25, 2012
Six cycles of doxorubicin and cyclophosphamide or Paclitaxel are not superior to four cycles as adjuvant chemotherapy for breast cancer in women with zero to three positive axillary nodes: Cancer and Leukemia Group B 40101Lawrence N Shulman, Constance T Cirrincione, Donald A Berry, et al.
Cancer|October 6, 2005
Developing a cancer-specific geriatric assessment: a feasibility studyArti Hurria, Supriya Gupta, Marjorie Zauderer, et al.
The Oncologist|April 13, 2019
Older-Patient-Specific Cancer Trials: A Pooled Analysis of 2,277 Patients (A151715)Dyda Dao, Tyler Zemla, Aminah Jatoi, et al.
European Journal of Cancer (Oxford, England : 1990)|March 19, 2022
Effects of capecitabine as part of neo-/adjuvant chemotherapy - A meta-analysis of individual breast cancer patient data from 13 randomised trials including 15,993 patientsMarion T van Mackelenbergh, Fenja Seither, Volker Möbus, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|April 30, 2018
Factors associated with falls in older adults with cancer: a validated model from the Cancer and Aging Research GroupTanya M Wildes, Ronald J Maggiore, William P Tew, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 18, 2014
Comparison of doxorubicin and cyclophosphamide versus single-agent paclitaxel as adjuvant therapy for breast cancer in women with 0 to 3 positive axillary nodes: CALGB 40101 (Alliance)Lawrence N Shulman, Donald A Berry, Constance T Cirrincione, et al.
Breast Cancer Research and Treatment|March 12, 2017
Using ePrognosis to estimate 2-year all-cause mortality in older women with breast cancer: Cancer and Leukemia Group B (CALGB) 49907 and 369901 (Alliance A151503)Gretchen G Kimmick, Brittny Major, Jonathan Clapp, et al.
Pageof 7